|Year : 2019 | Volume
| Issue : 4 | Page : 242-247
Vitamin D, 1,25-Dihydroxyvitamin D, FGF23, and graft function after renal transplantation
Sonia Mehrotra, Raj Kumar Sharma, Manas R Patel
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, India
|Date of Web Publication||20-May-2019|
Prof. Raj Kumar Sharma
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow - 226 014, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
Vitamin-D has immuno-modulatory properties besides its role in mineral and bone disorder (MBD) and could have a role in allograft outcome. Fifty-two chronic kidney disease patients on dialysis going for transplantation were prospectively studied before and after renal transplantation. FGF23, 25(OH) vitamin D, 1,25-Dihydroxyvitamin D, PTH, serum Ca, serum PO4, and e-GFR status were evaluated. Vitamin D deficiency was seen in 25.0% of recipients before transplant (26.09 ± 12.19 ng/mL) and in 48.1% at 6 months post-transplant (23.36 ± 15.11 ng/mL). 1,25-(OH)2D levels before transplant were 102.37 ± 108.44 pmol/L, which were less than control (143.30 ± 108.0 pmol/L) and decreased further to 46.20 ± 42.11 pmol/mL at 3 months and started increasing to 78.37 ± 60.12 pmol/mL at 6 months post-transplantation without vitamin D supplementation. The prevalence of hypophosphatemia after transplantation was 32.0%, hyperkalemia was 12.0%, elevated intact PTH levels at 3 and 6 months after transplant were seen in 66.7% and 30.8% patients, respectively. FGF-23 levels were high in 72.5% of patients before transplant (495.94 ± 690.68 pg/mL) and decreased to normal levels at 3 months post-transplant (31.63 ± 14.17 pg/m) (control 32.07 ± 9.78 pg/mL). Serum intact PTH levels were 379.54 ± 281.27 pg/mL before transplant and came down to 103.96 ± 68.34 at 3 months and 69.87 ± 116.03 at 6 months post-transplantation. There was trend of higher e-GFR at 1 year post-transplant in patients without vitamin D deficiency (levels ≥30 ng/mL). The dysregulated mineral metabolism continues in post-transplant despite improvement in renal function and normalization of FGF-23.
Keywords: 1,25-(OH)2 vitamin D, 25(OH) vitamin D deficiency, estimated GFR, FGF23, kidney transplantation
|How to cite this article:|
Mehrotra S, Sharma RK, Patel MR. Vitamin D, 1,25-Dihydroxyvitamin D, FGF23, and graft function after renal transplantation. Indian J Nephrol 2019;29:242-7
| Background|| |
Observational studies have demonstrated that vitamin D deficiency, defined as low serum total 25-hydroxy vitamin-D concentration, is associated with increased risks of death and diseases such as various cardiovascular diseases, malignancies, infectious diseases, diabetes, autoimmune diseases, and kidney diseases., The prevalence of vitamin D deficiency or insufficiency is high among patients with chronic kidney disease (CKD), especially patients with end-stage renal disease (ESRD) and kidney transplant recipients.,
1,25-dihydroxy vitamin-D (1,25-(OH)2D), the active functional metabolite of vitamin D, exerts its actions by binding to the vitamin D receptor (VDR) and altering the transcriptional rate of target genes. The protein products of these genes then carry out the functions of vitamin D, including the maintenance of serum Calcium (Ca) and phosphorus (P) homeostasis, regulation of cellular proliferation and differentiation, and modulation of the immune system.
The important final step of 1,25-(OH)2D synthesis is 1α-hydroxylation, which is catalyzed by 1α-hydroxylase. 1,25-(OH)2D deficiency is known to occur during the progression of CKD because the final hydroxylation step of 25-hydroxy vitamin D to 1,25-(OH)2D is mediated by kidney 1α-hydroxylase. 1,25-(OH)2D deficiency plays a major role in the development of secondary hyperparathyroidism, as 1,25-(OH)2D deficiency promotes parathyroid gland growth (hyperplasia) and increased parathyroid hormone (PTH) synthesis through loss of the ability to up-regulate VDR expression and activity within parathyroid cells. The end result is elevated serum PTH and abnormal Ca and P balance. Fibroblast growth factor–23 (FGF23), which is markedly increased in the early stages of CKD, has also been implicated in causing low 1,25-(OH)2D levels.
When the glomerular filtration rate (GFR) is approximately 33% of normal, the renal reserve of 1α-hydroxylase becomes inadequate, thereby resulting in reduced concentrations of 1,25-(OH)2D.,,, This causes development of secondary hyperparathyroidism. Inadequate levels of 1,25-(OH)2D decreases intestinal Ca absorption, resulting in reduced serum ionized Ca concentrations.
Vitamin D deficiency has been defined as 25(OH) vitamin D concentration <20 ng/mL, and insufficiency between ≥20 and <30 ng/mL. As defined in KDIGO guidelines, about 97% of patients in CKD stage 5 have vitamin D deficiency or insufficiency. In a rat model of chronic allograft nephropathy, administration of 1,25-(OH)2D prolonged allograft survival, decreased episodes of acute rejection, reduced proteinuria, and prevented histological changes associated with chronic allograft nephropathy. This suggests that vitamin D supplementation may reduce acute rejection and chronic allograft nephropathy through its interactions with the immune system.
1,25-(OH)2D analogues can act as adjuvant immuno-modulator therapy. They have been shown to prolong the survival of heart, liver, and kidney  allograft and inhibit not only acute but also chronic allograft rejection  in experimental models.
| Methods|| |
Fifty-two CKD patients on dialysis going for transplantation were prospectively studied before and after renal transplantation. FGF23, 25(OH) vitamin D, 1,25-(OH)2D, PTH, serum Ca, serum PO4, and estimated glomerular filtration rate (eGFR) were evaluated. All these patients received vitamin D supplementation (calcirol D2, 60,000 IU weekly for 6 weeks followed by once a month to maintain vitamin D level &z#62;30 ng/mL) before transplantation as per the requirement if they were vitamin D deficient. After transplantation, they were not given vitamin D supplementation.
Biochemical parameters were measured using biochemistry analyzer (AU480, Beckman Coulter). Human FGF23 (Intact) Elisa Kit (Immutopics, Inc. San Clemente, CA) was used to measure FGF-23 plasma concentration (https://www.quidel.com/research/immutopics/human-fgf-23-intact, Cat. 60-6100). 1,25-(OH)2D levels in serum were measured by ELISA (Immunodiagnostic Systems Ltd., https://www.idsplc.com/products/125-dihydroxy-vitamin-d-eia/, code: AC62F1) on an BIORAD-ELISA ELISA reader. 25(OH) vitamin D levels (http://www.laboratoireduquaivalliere.fr/notices%20analyses/FicheTechniqueVITD.pdf) and I-PTH (http://www.ilexmedical.com/files/PDF/IntactPTH_ARC.pdf) levels were assayed in serum by chemiluminescent microparticle immunoassay (CMIA) on an Architect i-1000 STAT (ABBOTT).
There is no consensus regarding normal 1,25 (OH)2D levels parameter in transplant recipients. We used 25th percentile of normal control as cutoff, for lower limit to define normal levels of 1,25 (OH)2D in >63 pmoL/lit (25th percentile of control group). Normal FGF-23 levels in our lab is 18.2-58.1 pg/mL. eGFR was measured using the CKD-Epidemiology Collaboration (CKD-EPI) equation which confers less underestimation of GFR in subjects with normal renal function.
25 (OH) Vitamin D levels of >30 ng/mL were considered sufficient and <20 ng/mL were deficient while 20-30 ng/mL were the insufficient vitamin D status (KDOQI guidelines).
Data was expressed as mean values ± standard deviation and as absolute and relative frequency for categorical variables. Statistical analysis was performed using SPSS software (Version 20.0). Graft function at 3 months, 6 months, and 1 year was compared between the groups by analysis of covariance (ANCOVA), taking into account covariates like e-GFR value at 1 year and 25-hydroxyvitamin D3 at baseline, 3 months, and 6 months. Various categorical variables were analyzed using Pearson correlation, Chi-square test, and Fisher's exact test. Statistical evaluation was used with eGFR as dependent variable and other factors as independent variables. Other statistical tests as appropriate were applied to various factors and variables.
| Results|| |
Fifty-two CKD (82.7% male, 17.3% female) patients on dialysis going for transplantation were prospectively studied before and after renal transplantation. Patient characteristics and demographic data are given in [Table 1]. After transplantation, prevalence of hypophosphatemia was 32.0% and of hypercalcemia was 12.0%. Elevated intact PTH levels were seen in 66.7% at 3 months, and in 30.8% at 6 months post-transplantation. Before transplantation, 71.2% of patients had hyperphosphatemia, while hypercalcemia was seen in 3.8% with elevated intact PTH levels seen in 92.2%. Raised FGF-23 levels were seen in 72.5% of patients before transplant (495.94 ± 690.68 pg/mL), which decreased to normal level at 3 months post-transplant (31.63 ± 14.17 pg/mL) (normal control 32.07 ± 9.78 pg/mL) [Table 2]. 25(OH) vitamin D levels indicated vitamin D deficiency in 25.0% of patients before transplant (26.09 ± 12.19 ng/mL). In post-transplant period, vitamin D deficiency was seen at 3 months in 43.1% (23.44 ± 10.64 ng/mL), while at 6 months, vitamin D deficiency further increased and was seen in 48.1% (23.36 ± 15.11 ng/mL). 1,25-(OH)2D levels before transplant were 102.37 ± 108.44 pmol/L which was less than control (143.30 ± 108.0 pmol/L) and decreased further to 46.20 ± 42.11 pmol/L at 3 months but showed an increase to 78.37 ± 60.12 pmol/L at 6 months post-transplantation (which was still less than controls) [Table 2]. Comparison between groups with e-GFR <60 and ≥60 mL/min/1.73 m 2 showed that post-transplant eGFR at 12 months did not correlate with vitamin D deficiency [Table 3] but showed correlation with vitamin D sufficiency [Table 4].
|Table 3: Descriptive Statistics of vitamin D (pre and post kidney transplant) compared with graft e-GFR category at 12 months (post-KT)|
Click here to view
Serum intact PTH levels were 379.54 ± 281.27 pg/mL before transplant and came down after transplant to 103.96 ± 68.34 pg/mL at 3 months and to 69.87 ± 116.03 pg/mL at 6 months.
All patients except one were on tacrolimus-based immunosuppression. Tacrolimus levels at 1 month were 13.47 ± 6.06 ng/mL with baseline normal target range of 10–15 ng/mL at 1 month.
There was no statistically significant difference (P value > 0.05) in all the parameters of mineral metabolisms studied in rejection and without rejection groups.
| Discussion|| |
Our study shows that there is high prevalence of vitamin D deficiency and insufficiency in patients with CKD going for transplantation, and it persists even after kidney transplantation in majority of patients, and this is also associated with secondary hyperparathyroidism (SHPT). This has also been shown in reports of publications of chronic kidney patients going for transplantation.,
Kidney is the main organ for metabolizing 25(OH) vitamin D to 1,25-(OH)2D (the biologically active form of vitamin D) by the action of the enzyme 1α-hydroxylase. Reduction in the GFR is associated with hyperphosphatemia and hypocalcemia. 1,25-(OH)2D deficiency results in the development of secondary hyperparathyroidism, as low levels of vitamin D stimulate synthesis of PTH, and loss of ability to regulate the expression and activity of VDR in parathyroid cells. Our results show that pre-transplant 1,25-(OH)2D levels were low. But 1,25-(OH)2D levels continued to be still low in the post-transplant period. In our study, we used vitamin D supplements only in the pre-transplant period. No vitamin D analogue was used in the post-transplant period. Transplant patients continued to have both low 25(OH) vitamin D and low 1,25-(OH)2D. This could be due to reduced renal mass after transplant. Although patients after transplant achieved improved renal function (as indicated by serum creatinine levels), the eGFR was still suboptimal in post-transplant period.
After transplant, though there is significant improvement in disorders of mineral metabolism, transplant patients continue to have vitamin D deficiency along with impaired graft function. After transplant, FGF23 levels got rapidly normalized as GFR improved. But 25(OH) vitamin D deficiency and low levels of 1,25-(OH)2D persisted after transplant.
In our study, FGF-23 levels rapidly decreased within normal limits within 3 months after transplantation. PTH and serum phosphorous levels also decreased significantly after kidney transplantation. Serum Ca and 1,25-(OH)2D levels showed an increasing trend after transplantation. In our study, there was no association between FGF-23 and 1,25-(OH)2D levels. This has also been reported in the literature. We did not use any vitamin D analogue supplementation in post-transplant period. Patients in our study showed a trend of increase in 1,25-(OH)2D levels after transplantation. At 6 months post-transplantation, 1,25-(OH)2D levels increased without any vitamin D supplementation. Vitamin D deficiency has been reported to be associated with risk of acute rejections in the post-transplant period. Vitamin D as an immune-modulator has the potential for preventing allograft rejection after transplantation.,, Even patients with good graft function after renal transplantation continue to have significant biochemical changes that can result in deterioration of bone quality, specifically in relation to vitamin D deficiency and hyperparathyroidism. Stavroulopoulos et al. showed that after transplant, vitamin D deficiency was very common in all of their renal transplant recipients and correlated with secondary hyperparathyroidism.
Prevalence of 25(OH) vitamin D deficiency at time of renal transplantation has been reported to be quite high. Renal function and vitamin D deficiency predict PTH levels in renal transplant patients. Management of both hyperparathyroidism and vitamin D deficiency needs to be done optimally after transplantation., In our study, vitamin D levels higher than 30 ng/mL were seen only in a minority of transplant recipients on follow-up. No association has been reported between 1,25-(OH)2D levels and eGFR after transplantation  as was also seen in our study. At 3 months post-transplantation, there was high prevalence of vitamin D deficiency along with raised PTH levels in our group of patients.
In vitro studies on cell cultures suggest that intra-cellular activity of 1,25-(OH)2D might be required to achieve adequate immune responses., Immune cells are both targets for 1,25-(OH)2D and are also able to locally activate 1,25-(OH)2D from circulating 25(OH) vitamin D. The anti-proliferative effects of 1,25-(OH)2D (i.e., stimulation of apoptosis, suppression of proliferation and differentiation, and decreased production of immunoglobulin) on B cells have been reported to be indirectly driven by T-helper cells. In our study, patients with vitamin D deficiency had a trend of decreased eGFR which could have a detrimental effect on graft outcome at 12 months post-transplant.
| Conclusion|| |
The dysregulated mineral metabolism continues after kidney transplant despite improvement in renal function and normalization of FGF-23. Although improved, 1,25-(OH)2D levels after transplantation were still less than normal healthy controls. This may be due to reduced renal mass and 1α-hydroxylase activity as compared to healthy controls with two kidneys as compared to transplant patients who have only one functioning kidney. In this study, there was trend of higher e-GFR at 1 year post-transplant in patients without vitamin D deficiency (levels ≥20 ng/mL). Future studies are required to test whether vitamin D supplementation early after kidney transplantation could improve allograft outcomes in larger number of patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Weinstock MA, Moses AM. Skin cancer meets vitamin D: The way forward for dermatology and public health. J Am Acad Dermatol 2009;61:720-4.
Christie FT, Mason L. Knowledge, attitude and practice regarding vitamin D deficiency among female students in Saudi Arabia: A qualitative exploration. Int J Rheumatic Dis 2011;14:e22-9.
González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. Am J Nephrol 2004;24:503-10.
Stavroulopoulos A, Cassidy MJD, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007;7:2546-52.
Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al.
The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49.
Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998;32(2 Suppl 2):S3-12.
Llach F, Velasquez F. Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects. Am J Kidney Dis 2001;38(5 Suppl 5):S20-33.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al.
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15.
Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, et al.
Serum levels of 1.25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55:1019-27.
Takamoto S, Onishi T, Morimoto S, Imanaka S, Tsuchiya H, Seino Y, et al.
Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: Effect of aluminum hydroxide administration. Nephron 1985;40:286-91.
Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1,25(OH)2D and 24,25(OH)2D. Clin Nephrol 1981;15:18-22.
Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J ClinInvest 1989;83:1349-55.
Piergiorgio B. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: An historic review. Clin Cases Miner Bone Metab 2009;6:210-9.
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
Hullett DA, Laeseke PF, Malin G, Nessel R, Sollinger HW, Becker BN. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005;18:1175-86.
Hullett DA, Cantorna MT, Redaelli C, Humpal-Winter J, Hayes CE, Sollinger HW, et al.
Prolongation of allograft survival by 1,25-dihydroxyvitamin D3, Transplantation 1998;66:824-8.
Redaelli CA, Wagner M, Tien YH, Mazzucchelli L, Stahel PF, Schilling MK, et al.
1-alpha, 25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 2001;34:926-34.
Fleseriu M, Licata AA. Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. Osteoporos Int 2007;18:363-8.
Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST. A Vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 1997;63:936-41.
Pablo UT, Marie M, Jean PH, Alexandre K, Jean JB, Martin F, et al.
Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis 2011;58:544-53.
Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, et al.
Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013;24:831-41.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al.
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
Economidou D, Dovas S, Papagianni A, Pateinakis P, Memmos D. FGF-23 Levels before and after renal transplantation. J Transplant 2009;2009:379082. doi: 10.1155/2009/379082.
Saber A, Fotuhi F, Rostami Z, Einollahi B, Nemati E. Vitamin D levels after kidney transplantation and the risk of cytomegalovirus infection. Nephrourol Mon 2015;7:e29677.
Park YJ, Kim SU, Lee KH, Lee JH, Kwon E, Jung HY, et al.
Vitamin D deficiency is associated with increased risk of bacterial infections after kidney transplantation. Korean J Intern Med 2017;32:505-13.
Stein EM, Shane E. Vitamin D in organ transplantation. Osteoporos Int 2011;22:2107-18.
Rocha MML, Andriolo A. Aspects of the blood chemistry of kidney transplant patients. J Bras Patol Med Lab 2015;51:284-90.
Sadlier DM, Magee CC. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: A prospective study. Clin Transplant 2007;21:683-8.
Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant 2006;21:2621-4.
Querings K1, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006;91:526-9.
Keyzer CA, Riphagen IJ, Joosten MM, Navis G, Muller Kobold AC, Kema IP. Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab 2015;100:81-9.
Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: A helpful immuno-modulator. Immunology 2011;134:123-39.
Hewison M. Vitamin D and immune function: Autocrine, paracrine orendocrine? Scand J Clin Lab Invest Suppl 2012;243:92-102.
Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74:657-61.
[Table 1], [Table 2], [Table 3], [Table 4]